Thermo Fisher Scientific Deferred Revenue decreased by 5.0% to $2.71B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.0%, from $2.85B to $2.71B. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows an upward trend with a 16.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase is a strong leading indicator of future revenue growth and healthy sales momentum.
Cash collected from customers in advance of providing services or delivering products, expected to be recognized as reve...
A critical metric for SaaS and cloud peers (like Salesforce or Amazon) to gauge the health of the subscription pipeline.
deferred_revenue_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.47B | $1.44B | $2.66B | $2.87B | $2.72B | $2.57B | $2.60B | $2.66B | $2.59B | $2.55B | $2.69B | $2.63B | $2.59B | $2.66B | $2.85B | $2.87B | $2.81B | $2.85B | $2.71B |
| QoQ Change | — | -1.9% | +84.1% | +8.1% | -5.2% | -5.7% | +1.3% | +2.3% | -2.7% | -1.7% | +5.6% | -2.1% | -1.6% | +2.8% | +7.1% | +0.5% | -2.1% | +1.7% | -5.0% |
| YoY Change | — | — | — | — | +85.2% | +78.0% | -2.0% | -7.3% | -4.8% | -0.8% | +3.4% | -1.1% | +0.0% | +4.6% | +6.1% | +8.9% | +8.3% | +7.1% | -5.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.